Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

Director/PDMR Shareholding

2 Nov 2005 09:41

Angle PLC02 November 2005 NOTIFICATION OF TRANSACTIONS OF DIRECTORS, PERSONS DISCHARGING MANAGERIALRESPONSIBILITY OR CONNECTED PERSONS This form is intended for use by an issuer to make a RIS notification requiredby DR 3.1.4R(1). Please complete all relevant boxes should in block capital letters. 1. Name of the issuerAngle Plc 2. State whether the notification relates to (i) a transaction notified inaccordance with DR 3.1.4R(1)(a); or(ii) DR 3.1.4(R)(1)(b) a disclosure made in accordance with section 324 (asextended by section 328) of the Companies Act 1985; or(iii) both (i) and (ii)Both 3. Name of person discharging managerial responsibilities/directorIan Griffiths 4. State whether notification relates to a person connected with a persondischarging managerial responsibilities/director named in 3 and identify theconnected personN/a 5. Indicate whether the notification is in respect of a holding of the personreferred to in 3 or 4 above or in respect of a non-beneficial interestas in 3 above6. Description of shares (including class), debentures or derivatives orfinancial instruments relating to sharesOrdinary shares of 10p each 7. Name of registered shareholders(s) and, if more than one, the number ofshares held by each of themIan Griffiths 8 State the nature of the transactionPurchase of Ordinary Shares 9. Number of shares, debentures or financial instruments relating to sharesacquired8932 10. Percentage of issued class acquired (treasury shares of that class shouldnot be taken into account when calculating percentage)0.05% 11. Number of shares, debentures or financial instruments relating to sharesdisposedn/a 12. Percentage of issued class disposed (treasury shares of that class shouldnot be taken into account when calculating percentage)n/a 13. Price per share or value of transaction£1.115 per share 14. Date and place of transaction1 November 2005 15. Total holding following notification and total percentage holding followingnotification (any treasury shares should not be taken into account whencalculating percentage)529,546 shares. 3.17% 16. Date issuer informed of transaction1 November 2005 If a person discharging managerial responsibilities has been granted options bythe issuer complete the following boxes 17 Date of grant .................................... 18. Period during which or date on which it can be exercised .................................... 19. Total amount paid (if any) for grant of the option .................................... 20. Description of shares or debentures involved (class and number) ........................................................................ 21. Exercise price (if fixed at time of grant) or indication that price is to befixed at the time of exercise .................................... 22. Total number of shares or debentures over which options held followingnotification .................................... 23. Any additional information .................................... 24. Name of contact and telephone number for queriesIan Griffiths 01483 295830 Name and signature of duly authorised officer of issuer responsible for makingnotification .................................... Date of notification2 November 2005 END (1) An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24.(2) An issuer making a notification in respect of a derivative relating the shares of the issuer should complete boxes 1 to 4, 6, 8,13, 14, 16, 23 and 24.(3) An issuer making a notification in respect of options granted to a director /person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24.(4) An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
27th Sep 20217:00 amRNSParsortix demonstrates ability to isolate CTCs
22nd Sep 20217:00 amRNSStudy shows use of Parsortix to assess PD-L1
20th Sep 20217:00 amRNSParsortix enables gene expression analysis in mPCa
7th Sep 20217:00 amRNSNotice of Interim Results and Webcast
24th Aug 20217:00 amRNSDirector/PDMR Shareholding
9th Aug 20217:00 amRNSStudy highlights superior performance of Parsortix
6th Aug 20211:17 pmRNSIssue of Equity
3rd Aug 20213:13 pmRNSIssue of Equity
28th Jul 20217:00 amRNSContract secured for bespoke assay development
9th Jul 20217:00 amRNSHarvesting CTCs from brain metastasis patients
7th Jul 20216:34 pmRNSDirector/PDMR Shareholding
2nd Jul 202110:45 amRNSIssue of Equity
30th Jun 20213:44 pmRNSResult of AGM
25th Jun 20217:00 amRNSResult of Accelerated Bookbuild
24th Jun 20216:28 pmRNSAccelerated bookbuild to raise up to £20m
18th Jun 202111:42 amRNSAnnual General Meeting update
18th Jun 20217:00 amRNSctDNA and CTCs have differences in EGFR mutations
4th Jun 20217:00 amRNSUpdate on submission for FDA clearance
1st Jun 20217:00 amRNSPotential to prevent breast cancer relapse
20th May 20217:00 amRNSParsortix demonstrates oesophageal cancer utility
19th May 20214:37 pmRNSExercise of options and total voting rights
11th May 20217:00 amRNSParsortix study uncovers targets in TNBC patients
30th Apr 202111:22 amRNSExercise of options and total voting rights
29th Apr 20217:00 amRNSPreliminary Results
26th Apr 20217:00 amRNSOvarian cancer study patient enrolment completed
19th Apr 20212:05 pmRNSSecond Price Monitoring Extn
19th Apr 20212:00 pmRNSPrice Monitoring Extension
19th Apr 202111:05 amRNSSecond Price Monitoring Extn
19th Apr 202111:00 amRNSPrice Monitoring Extension
16th Apr 20217:00 amRNSFirst large-scale pharma services contract secured
15th Apr 20214:10 pmRNSNotice of Preliminary Results and Webcast
12th Apr 20217:00 amRNSANGLE's Parsortix system showcased at AACR 2021
30th Mar 20217:00 amRNSGlobal launch of clinical services laboratories
4th Mar 20217:00 amRNSUpdate on submission for FDA clearance
18th Feb 20217:00 amRNSParsortix-harvested CTCs uncover novel biomarker
8th Feb 20217:00 amRNSParsortix: Dynamic assessment of patient response
29th Jan 20217:00 amRNSParsortix demonstrates high capture rate of CTCs
26th Jan 20211:00 pmRNSHolding(s) in Company
20th Jan 20217:00 amRNSResearch confirms high performance of Parsortix
12th Jan 20217:00 amRNSChange of Auditor
5th Jan 20217:00 amRNSIssue of Equity
9th Dec 20207:00 amRNSParsortix can capture single cancer cell in sample
20th Nov 20204:18 pmRNSHolding(s) in Company
18th Nov 20204:51 pmRNSHolding(s) in Company
13th Nov 202010:46 amRNSResult of General Meeting
3rd Nov 20202:54 pmRNSDirector/PDMR Shareholding
29th Oct 20207:00 amRNSInterim Results
27th Oct 20206:28 pmRNSResult of Placing & Notice of General Meeting
27th Oct 20207:00 amRNSAccelerated bookbuild to raise up to £20m
20th Oct 20207:00 amRNSSubmission accepted by FDA for substantive review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.